Total Funding
78
60
Total FundingPost-IPO Equity raised
Growth Score
-3 pts
Heat Score
-16 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
7968
Serina Therapeutics employs its proprietary polymer technology to develop treatments for cancer, inflammation, pain and metabolic disorders.
- J. Milton Harris: Co-Founder and Chairman of the Board
- Randall Moreadith: Chief Development OfficerPast Role: Serina Therapeutics, President and Chief Executive Officer
About the Company
Serina Therapeutics is a privately-held pharmaceutical company that is advancing novel therapeutics for cancer, inflammation, pain, and metabolic disorders using its proprietary polymer technology. They have created new pharmaceutical candidates using polyoxazoline (POZ), a safe, water-soluble polymer to which they can attach a variety of small
molecules, proteins, peptides, and DNA. The attachment of these molecules to polymers of POZ typically confers a unique pharmacokinetic profile that is markedly different from the parent compound, and this profile may confer advantages in terms of safety and efficacy.
